Helicobacter pylori eradication provides no benefit for rheumatic patients receiving non-steroidal anti-inflammatory (NSAID) and omeprazole therapy.
The eradication of Helicobacter pylori does not appear to affect the incidence or severity of gastrointestinal symptoms in infected rheumatic patients who are receiving long term treatment with conventional nonsteroidal anti-inflammatory drugs and omeprazole.
Bernard Bannwarth, MD, at the Université Victor Segalen, in Bordeaux, France, and colleagues conducted a multicentre, open label, parallel group study of 919 patients requiring long term NSAID therapy for rheumatic disease.
Patients who tested positive for H. pylori were randomized to receive either eradication therapy (omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d. for seven days) or no therapy. Both these groups and the H. pylori-negative patients were given 20 mg of omeprazole daily, along with NSAID for the study duration of five to eight weeks.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!